Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia

Neuroscience. 2011 Dec 15:198:245-51. doi: 10.1016/j.neuroscience.2011.07.070. Epub 2011 Aug 5.

Abstract

Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associated to abnormally high levels of synaptic dopamine (DA) in the caudate-putamen of dyskinetic L-DOPA-treated patients. High striatal extracellular DA levels have also been found in dyskinetic 6-OHDA-lesioned rats as compared to non-dyskinetic ones, suggesting that extracellular DA levels may play a key role in the induction of dyskinesia. In this article we review the evidences pointing to the serotonin system as the primary cause for the abnormally high levels of L-DOPA-derived extracellular DA in Parkinson's disease, and we discuss the feasibility of a therapeutic approach targeting this system.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / adverse effects*
  • Disease Models, Animal
  • Dopamine / metabolism
  • Dyskinesia, Drug-Induced / diagnostic imaging
  • Dyskinesia, Drug-Induced / pathology*
  • Humans
  • Levodopa / adverse effects*
  • Oxidopamine / toxicity
  • Parkinson Disease / drug therapy
  • Parkinson Disease / etiology
  • Positron-Emission Tomography
  • Presynaptic Terminals / metabolism*
  • Rats
  • Serotonergic Neurons / physiology
  • Serotonin / metabolism*

Substances

  • Antiparkinson Agents
  • Serotonin
  • Levodopa
  • Oxidopamine
  • Dopamine